Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study

Abstract

Our study recommends reducing the dose regimen of NB-UVB and consequently the cumulative UVB dose by using the suberythemogenic dosing schedule even in dark skin population.

Psoriasis in Patients of Color: Differences in Morphology, Clinical Presentation, and Treatment

“…Suberythemogenic dosing-70% of minimal erythema dose-of narrowband UVB treatments has shown the same efficacy as using minimal erythema dose in patients with darker skin types in addition to fair-skinned patients. 8 Although we found poor efficacy of systemic treatments in patient 1, to our knowledge, studies examining the efficacy of systemic therapeutic options have not shown differences in patients of color. 6,13 Studies show similar efficacy in treatments among races, particularly biologic therapies.…”

“…For clinicians, more attention on the differences would help make earlier diagnoses, personalize physician-patient conversations, and advocate for further education on this issue in residency training programs. Potentially greater impact on QOL with scalp psoriasis 2,5,a Greater BSA involvement in Asian patients 6 More severe disease at presentation 7,a Treatment Preference for foams and lotions for scalp 2,a UV consideration for prevention of hyperpigmentation 8 No known differences in efficacy of systemic treatments 5 Patients with skin of color underrepresented in clinical trials 9 Reduced patient recognition of certain treatments 10 Psychosocial impact Higher DLQI at baseline 6,a Abbreviations: QOL, quality of life; BSA, body surface area; DLQI, dermatology life quality index.…”

A review of phototherapy protocols for psoriasis treatment

“…However, 0.7 MED is equally effective in darkskinned individuals and should be preferentially used as the starting dose for those patients. 38 NB-UVB treatment is theoretically possible every 24 hours because the erythema peak occurs between 8 and 24 hours after irradiation. 18 However, daily treatment is not better than therapy every other day.…”

S3‐Leitlinie zur Therapie der Psoriasis vulgaris Update 2011

“…Für diese Modalität wurden Studien mit Behandlungsfrequenzen von zwei [181], drei [182][183][184][185][186], fünf [187,188] [191], zweimal [192][193][194], dreimal [147,184,195,196] oder 4 x/Wo [193,197] In mehreren kleinen [195,[199][200][201] sowie einer größeren nichtrandomisierten Studie [202] [197,212] treten jedoch mit ca. 5 % eher selten auf [197].…”